First Time Loading...

Nektar Therapeutics
NASDAQ:NKTR

Watchlist Manager
Nektar Therapeutics Logo
Nektar Therapeutics
NASDAQ:NKTR
Watchlist
Price: 1.32 USD Market Closed
Updated: Apr 29, 2024
Section:
 

Wall Street
Price Targets

NKTR Price Targets Summary
Nektar Therapeutics

Wall Street analysts forecast NKTR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NKTR is 2.04 USD with a low forecast of 1.01 USD and a high forecast of 3.15 USD.

NKTR Lowest Forecast
Wall Street Target
1.01 USD
23% Downside
NKTR Average Forecast
Wall Street Target
2.04 USD
55% Upside
NKTR Highest Forecast
Wall Street Target
3.15 USD
139% Upside
Lowest
Price Target
1.01 USD
23% Downside
Average
Price Target
2.04 USD
55% Upside
Highest
Price Target
3.15 USD
139% Upside
Nektar Therapeutics Competitors:
Price Targets
000623
Jilin Aodong Pharmaceutical Group Co Ltd
146% Upside
H
600566
Hubei Jumpcan Pharmaceutical Co Ltd
8% Upside
BAI
BenevolentAI SA
292% Upside
4503
Astellas Pharma Inc
47% Upside
000623
Jilin Aodong Pharmaceutical Group Co Ltd
146% Upside
H
600566
Hubei Jumpcan Pharmaceutical Co Ltd
8% Upside
BAI
BenevolentAI SA
292% Upside
4503
Astellas Pharma Inc
47% Upside
CAPLIPOINT
Caplin Point Laboratories Ltd
21% Upside
003000
Bukwang Pharm Co Ltd
370% Upside
CPH
Cipher Pharmaceuticals Inc
39% Upside
IPCALAB
IPCA Laboratories Ltd
15% Downside

Revenue
Forecast

Revenue Estimate
Nektar Therapeutics

For the last 8 years the compound annual growth rate for Nektar Therapeutics's revenue is -11%. The projected CAGR for the next 3 years is -10%.

-11%
Past Growth
-10%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Nektar Therapeutics

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-14%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Nektar Therapeutics

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-8%
Average Miss
What are analyst estimates?

See Also

Summary
NKTR intrinsic value, competitors valuation, and company profile.
DCF Valuation
NKTR stock valuation using Discount Cash Flow valuation method.
Relative Valuation
NKTR stock valuation using valuation multiples.
Wall Street Estimates
NKTR price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
NKTR stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is NKTR's stock price target?
Price Target
2.04 USD

According to Wall Street analysts, the average 1-year price target for NKTR is 2.04 USD with a low forecast of 1.01 USD and a high forecast of 3.15 USD.

What is Nektar Therapeutics's Revenue forecast?
Projected CAGR
-10%

For the last 8 years the compound annual growth rate for Nektar Therapeutics's revenue is -11%. The projected CAGR for the next 3 years is -10%.

ALPHA SPREAD
Join more than 132,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.